Targeted therapy in renal cell carcinoma: Moving from molecular agents to specific immunotherapy

World Journal of Urology

Volumn 32, Issue 1, 2014, Pages 31-38

  Bedke, Jens ^a   Gouttefangeas, Cécile ^a   Singh Jasuja, Harpreet ^b   Stevanović, Stefan ^a   Behnes, Carl Ludwig ^c   Stenzl, Arnulf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

IMA901; Immune therapy; Renal cell carcinoma; Tyrosine kinase inhibitor; Vaccination

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

DRUG ANTAGONISM; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; METHODOLOGY; MOLECULARLY TARGETED THERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893663818     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1033-3     Document Type: Review

References (57)

1. Lokich J (1997) Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 20: 416-418.
2. Dengjel J et al (2006) Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12: 4163-4170.
3. Saenz-Lopez P et al (2010) Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens 75: 110-118.
4. Attig S et al (2009) Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 69: 8412-8419.
5. Schendel DJ et al (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 151: 4209-4220.
6. Ljungberg B et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58: 398-406.
7. Yang JC et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127-3132.
8. Atkins M et al (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11: 3714-3721.
9. Pantuck AJ et al (2005) Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings No. 16S: 4535.
10. Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107: 2409-2414.
11. van der Vliet HJ et al (2007) Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 13: 2100-2108.
12. Kruck S et al (2012) Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 12: 777-785.
13. Escudier B et al (2012) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(suppl 7): vii65-71.
14. Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
15. Hipp MM et al (2008) Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111: 5610-5620.
16. Finke JH et al (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14: 6674-6682.
17. Ko JS et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15: 2148-2157.
18. Porta C et al (2011) Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer 2: 333-338.
19. Abraham RT, Wiederrecht GJ (1996) Immunopharmacology of rapamycin. Annu Rev Immunol 14: 483-510.
20. Rammensee HG, Falk K, Rotzschke O (1993) Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11: 213-244.
21. van der Bruggen P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
22. Weinschenk T et al (2002) Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 62: 5818-5827.
23. Seremet T, Brasseur F, Coulie PG (2011) Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J 17: 325-330.
24. Brookman-May S et al (2011) Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev Vaccines 10: 837-852.
25. Wierecky J et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66: 5910-5918.
26. Biswas S, Eisen T (2009) Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat Rev Clin Oncol 6: 478-487.
27. Jocham D et al (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594-599.
28. Wood C et al (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372: 145-154.
29. Escudier B (2012) Emerging immunotherapies for renal cell carcinoma. Ann Oncol 23(suppl 8): viii35-40.
30. Engels B et al (2005) Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther 16: 799-810.
31. Britten CM et al (2008) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57: 289-302.
32. van der Burg SH et al (2011) Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 3: 108ps144.
33. Welters MJ et al (2012) Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother 61: 967-978.
34. Walter S et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med in press.
35. Welters MJ et al (2010) Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 107: 11895-11899.
36. Amato RJ et al (2010) Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 16: 5539-5547.
37. Sampson JH et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 4722-4729.
38. Feyerabend S et al (2009) Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69: 917-927.
39. Bedke J et al (2012) Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur Urol Suppl 11: e76-ea.
40. Uemura H et al (2006) A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 12: 1768-1775.
41. Rosenberg SA et al (1999) Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163: 1690-1695.
42. Weber J et al (2003) Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97: 186-200.
43. Curiel TJ (2007) Tregs and rethinking cancer immunotherapy. J Clin Invest 117: 1167-1174.
44. Kusmartsev S et al (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14: 8270-8278.
45. Mantovani A et al (2008) Cancer-related inflammation. Nature 454: 436-444.
46. Murdoch C et al (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618-631.
47. Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
48. Yang JC et al (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30: 825-830.
49. Study of BMS-936558 vs. everolimus in pre-treated advanced or metastatic clear-cell RCC. http://clinicaltrials. gov/ct2/show/NCT01668784.
50. Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
51. El Mir S, Triebel F (2000) A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol 164: 5583-5589.
52. Brignone C et al (2009) A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15: 6225-6231.
53. Escudier B et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28: 2144-2150.
54. Rini BI et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28: 2137-2143.
55. BMS-936558 (MDX-1106) In combination with sunitinib or pazopanib in subjects with metastatic renal cell carcinoma (RCC). http://clinicaltrials. gov/ct2/show/NCT01472081.
56. Figlin RA et al (2011) Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J Clin Oncol 29:(suppl; abstr 2532).
57. IMA901 in patients receiving sunitinib for advanced/metastatic renal cell carcinoma. http://clinicaltrials. gov/ct2/show/NCT01265901.